We're hiring! The @WilmotCancer GU Medical Oncology program at the @UofR is recruiting genitourinary medical oncologists to join our team. Why Wilmot? • A rapidly growing NCI-designated cancer center • The largest clinical trials program in the region • Rochester and the Finger Lakes: a region known for an exceptional quality of life Whether you're an established GU oncologist or finishing fellowship and looking for a place to build your career, we'd love to talk. Message me directly to learn more, and please share with any colleagues who might be a good fit. #GUOncology #MedicalOncology #HemOnc #Oncology #Hiring

Shanah Tovah! Happy, healthy, and sweet new year to all!

Very excited to welcome four outstanding new faculty to the Lank Center for Genitourinary Oncology @DanaFarber 1) Dr. Nazli Dizman @NazliDizman 2) Dr. Brian Russell @brian_russell39 3) Dr. Hamid Emamekhoo @HamidEmamekhoo 4) Pr. Neeraj Agarwal @neerajaiims They bring complementary expertise spanning clinical investigation, microbiome science, informatics, quality improvement, education, and GU oncology. Hamid and Neeraj will also take on important broader institutional leadership roles @DanaFarber and @Harvard Cancer Consortium @df_hcc We are fortunate to have them—and the @DanaFarber_GU and our patients are in very good hands. Welcome to @CityOfBoston and @DanaFarber!

Many reasons to be cautious about overtreating BCR… Here’s how @LaurenOLoughli3 presents this complex discussion to pts: urotoday.com/video-lectures/…

With befitting fanfare, we bid farewell to these 8 exceptional @BIDMC_HOFellows who have lived, learned, and cared with the integrity, intellect, and generosity of spirit that define our community. We are so proud to be your colleagues and friends! @rushadpatell

🎉 Congratulations to our outstanding class of outgoing @BIDMC_HOFellows! We are grateful to have mentored you along your professional journeys and so excited for your exciting futures ahead.

Congrats to the graduating GU (and all) @BIDMC_HOFellows of 2026! And a clean sweep of the nursing/admin awards for our stellar GU team!

📢 PALLIATIVE CARE IS SIMPLY GOOD CARE AIMED TO MEET PEOPLE’S NEEDS! It is part of routine care. It is NOT mutually exclusive with active treatment. There is never “nothing we can do” - there is always something we can do to help. It’s not always “find a new shiny drug.” #ASCO26

SENTRY is an IIT, phase II, for localized HR (N0 on PSMA). RT+18m ADT vs RT+6m ADT/ARPI. RSI MRI and PSMA PET required. Focal boost required if feasible. MDT alone encouraged for oligomet recurrence. Primary endpoint: FFS; “failure” of initial Rx plan = salvage ADT or CRPC.

@DanaFarber and @DanaFarber_GU 's very own @AtishChoudhury presents compelling de-intensification data from A-DREAM/A032101 in mHSPC: 41% of favorable responders remained treatment-free with testosterone recovery 18 months after ADT + ARPI interruption, supporting treatment holidays as a promising strategy in selected pts. #ASCO26 #ProstateCancer @OncoAlert @ASCO @OncBrothers

Congratulations to our incredible GI Medical Oncologist @BrunoBockorny on his work on KMT2C mutation in GI malignancies! @BIDMC_CancerCtr #ASCO2026

Congrats to @AtishChoudhury and @CaPsurvivorship for their oral presentations today and how we can adapt treatment interruption and cognitive change from treatment for men with advanced prostate cancer. Huge efforts from them and the study teams @ALLIANCE_org

Congrats @AtishChoudhury 👉Can we safely de-intensify Rx in exceptional responders with mHSPC/ mAPMS #prostatecancer ? #ASCO2026 A-DREAM data👉Rx holiday after ADT + ARPI may be feasible, with 41% remaining treatment-free with testosterone recovery at 18 mos @OncoAlert @urotoday

📐 HR 0.68 = a 32% relative risk reduction in recurrence at any given moment during follow-up. That sounds like a large benefit. But the absolute numbers tell a different story: BCG alone: 81.6% disease-free at 2 years BCG + durvalumab: 86.5% disease-free at 2 years Absolute difference: ~5% Since BCG already works well, a big relative reduction maps to a modest absolute gain. @MaxKates @UrogerliMD @JoshMeeks

Ab#5001 @ASCO #ASCO26 by @ChrisSweens1👉 bit.ly/4dnFUvD👉Decipher Prostate Genomic Classifier (DGC) predicts benefit w/ triplet Rx in #prostatecancer👉DGC>0.85 is predictive of benefit from adding docetaxel to ADT+Enza👇@Prof_IanD @OncoAlert @urotoday @PCF_science

Society guidelines matter. This is especially concerning for rural areas where family medicine training predominates.

Not all prostate cancer is “cold”! And the primary TIME may have relevance for later BCR/micrometastatic states! Congrats @DYangMD and team!

Heidi on HEIDI